Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Werte in diesem Artikel
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference.
Conference Details: | |
Presentation | |
Date: | Wednesday, January 14, 2026 |
Time: | 4:30 p.m. Pacific Time |
Location: | San Francisco, CA |
A webcast of the presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference-302654454.html
SOURCE Novavax, Inc.
Ausgewählte Hebelprodukte auf Novavax
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novavax
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Novavax Aktie News
Novavax Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novavax nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.08.19 | Novavax Buy | H.C. Wainwright & Co. | |
| 11.12.18 | Novavax Outperform | Oppenheimer & Co. Inc. | |
| 29.03.18 | Novavax Buy | Seaport Global Securities | |
| 05.01.18 | Novavax Buy | B. Riley FBR, Inc. | |
| 20.09.16 | Novavax Neutral | Chardan Capital Markets |
